News

News Subscription

Aug 16. 2021 / Ad hoc announcement
Basilea awarded additional USD 4.3 million by BARDA to support phase 3 development of ceftobiprole
Read more
Download
Jul 29. 2021
Basilea announces U.S. FDA Orphan Drug Designation granted to lisavanbulin for the treatment of malignant glioma
Read more
Download
Jul 26. 2021 / Ad hoc announcement
Basilea’s partner Asahi Kasei Pharma prepares NDA filing for the marketing authorization of isavuconazole in Japan based on positive phase 3 study results
Read more
Download
Jul 14. 2021 / Ad hoc announcement
Basilea announces distribution agreement with JSC Lancet for antibiotic Zevtera® (ceftobiprole) covering Russia and the Eurasian Economic Union
Read more
Download
Jun 07. 2021
Basilea reports new prevalence data for EB1, a potential response-predictive biomarker for lisavanbulin in glioblastoma and other tumor types, at ASCO Annual Meeting
Read more
Download
May 31. 2021
Basilea provides updates on efficacy data with derazantinib in bile duct cancer and on ongoing clinical programs in urothelial and gastric cancer
Read more
Download
May 19. 2021
Basilea awarded CARB-X grant of up to USD 2.7 million to develop novel-class antibiotic
Read more
Download
Apr 21. 2021
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
Read more
Download
Apr 01. 2021
Basilea announces closing of previously announced transaction regarding divestment of its Chinese R&D subsidiary
Read more
Download
Mar 24. 2021
Basilea reports positive interim results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene mutation- or amplification-positive patients with bile duct cancer (iCCA)
Read more
Download